---
layout: post
title: "中国国药疫苗第三针加强补种方案已提交审批"
date: 2021-09-05T10:38:42.123Z
author: 联合早报
from: https://www.zaobao.com/realtime/china/story20210905-1190655
tags: [ 联合早报 ]
categories: [ 联合早报 ]
---
<!--1630860480000-->
[中国国药疫苗第三针加强补种方案已提交审批](https://www.zaobao.com/realtime/china/story20210905-1190655)
------

<div>
<p>中国国药集团中国生物据报已提交冠病灭活疫苗第三针加强补种方案，正等待方案审批通过。</p><p>《中国日报》今天独家报道上述消息，并引述中国国药集团中国生物纪委书记陈坤说，实验数据表明，在完成该公司灭活疫苗两针剂免疫程序六个月后，开展加强接种，受试者体内抗体水平最高可提升5至10倍，可大幅度提升免疫效果。</p><p>陈坤也说，该方案建议，针对老年人、窗口性服务业从业者等特殊群体，在完成两剂接种免疫程序后六个月至一年内，可再接种一剂加强针。</p><section id="imu"><div id="dfp-ad-imu1">        </div></section><p>据报道，中国国药集团中国生物独立自主在三条技术路线（灭活、基因重组、mRNA）上布局研发了四款疫苗。旗下北京生物制品研究所和武汉生物制品研究所的两款冠病灭活疫苗均已获批上市。<br> </p>      <div id="innity-in-post"></div><div id="dfp-ad-midarticlespecial">        </div>      <a href="https://subscribe.sph.com.sg/promotions/zbpe-3-months-99-cents-promotion/?utm_campaign=zbpe399&utm_medium=sph-publication&utm_source=zb&utm_content=subscribelink-free-endofarticle" target="_blank"><img class="view-desktop lazyload  " data-src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_desktop-zbpe399_2.png?dHEiGouxxZpWwWTJE04dyGyUN74JOU2z" alt style="width:100%;" pinger-seen="true" src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_desktop-zbpe399_2.png?dHEiGouxxZpWwWTJE04dyGyUN74JOU2z" referrerpolicy="no-referrer"></a>      <a href="https://subscribe.sph.com.sg/promotions/zbpe-3-months-99-cents-promotion/?utm_campaign=zbpe399&utm_medium=sph-publication&utm_source=zb&utm_content=subscribelink-free-endofarticle" target="_blank"><img class="view-mobile lazyload " data-src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_mobile-zbpe399_2.png?qZnBcIGCJvPR8A2IAZOZuOxdoGZDatiI" alt pinger-seen="true" src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_mobile-zbpe399_2.png?qZnBcIGCJvPR8A2IAZOZuOxdoGZDatiI" referrerpolicy="no-referrer"></a>
</div>
